================================================================================
BIOTECH INSIDER + HIRING SIGNALS REPORT
Generated: 2024-01-15 09:30:00
================================================================================

SCORING METHODOLOGY
----------------------------------------
Composite Score: Weighted sum of all signals with time-decay
  - Recent signals weighted more heavily (30-day half-life)
  - Score range: -10 (very bearish) to +10 (very bullish)

Confidence: Based on signal count and quality
  - Range: 0.0 (low) to 1.0 (high)

Recommendations:
  STRONG BUY:  Score >= 6.0, Confidence >= 0.70
  BUY:         Score >= 3.0, Confidence >= 0.50
  NEUTRAL:     Between BUY and SELL thresholds
  SELL:        Score <= -3.0, Confidence >= 0.50
  STRONG SELL: Score <= -6.0, Confidence >= 0.70

================================================================================
SIGNAL SUMMARY
================================================================================

Ticker    Score    Conf    Rec           Insider    Inst    Hiring
--------  -------  ------  ------------  ---------  ------  --------
MRNA      +6.5     75%     STRONG BUY    +3.5       +2.0    +3.0
VRTX      +4.2     65%     BUY           +2.5       +1.5    +2.0
CRSP      +3.8     60%     BUY           +1.5       +2.0    +1.5
BEAM      +1.2     45%     NEUTRAL       +0.5       +0.5    +0.5
EDIT      -2.5     55%     NEUTRAL       -1.5       -1.0    +0.0
NTLA      +2.1     50%     NEUTRAL       +1.0       +0.5    +1.0
ALNY      +5.1     68%     BUY           +2.0       +2.5    +1.5
BLUE      -5.2     70%     SELL          -2.5       -1.5    -2.0
SAGE      -6.8     75%     STRONG SELL   -3.0       -2.5    -2.5
REGN      +3.5     55%     BUY           +1.5       +1.0    +1.5

================================================================================
DETAILED SIGNAL BREAKDOWN
================================================================================

--- MRNA (Moderna Inc) ---
Composite Score: +6.50
Confidence: 75%
Recommendation: STRONG BUY

Score Breakdown:
  Insider Score:       +3.50
  Institutional Score: +2.00
  Hiring Score:        +3.00

Contributing Signals:
  [+3.75] CEO_PURCHASE: CEO bought $200K of shares (10 days ago)
  [+3.35] COMMERCIAL_BUILDUP: 8 commercial roles posted (15 days ago)
  [+2.50] FUND_NEW_POSITION: Baker Bros initiated position (Q3 2023)
  [+1.52] FUND_INCREASE_50: RA Capital increased 60% (50 days ago)

Analysis: Strong bullish convergence across all signal categories. CEO open
market purchase (not 10b5-1 plan) suggests high confidence in near-term
catalysts. Commercial hiring buildup indicates potential product launch
preparation. Multiple top biotech funds establishing/increasing positions.

--- VRTX (Vertex Pharmaceuticals) ---
Composite Score: +4.20
Confidence: 65%
Recommendation: BUY

Score Breakdown:
  Insider Score:       +2.50
  Institutional Score: +1.50
  Hiring Score:        +2.00

Contributing Signals:
  [+2.50] CFO_PURCHASE: CFO bought $100K of shares (20 days ago)
  [+2.00] CLINICAL_EXPANSION: 5 clinical operations roles (25 days ago)
  [+1.90] FUND_INCREASE_50: RA Capital increased 60% (45 days ago)
  [+1.20] REGULATORY_EXPANSION: 3 regulatory affairs roles posted

Analysis: CFO purchase is notable signal - CFOs rarely buy unless confident
in financials. Clinical operations expansion suggests trial activity
acceleration. Regulatory hiring may indicate FDA submission preparation.

--- CRSP (CRISPR Therapeutics) ---
Composite Score: +3.80
Confidence: 60%
Recommendation: BUY

Score Breakdown:
  Insider Score:       +1.50
  Institutional Score: +2.00
  Hiring Score:        +1.50

Contributing Signals:
  [+2.00] FUND_NEW_POSITION: Perceptive Advisors initiated position
  [+1.50] DIRECTOR_PURCHASE: Board director bought $75K
  [+1.20] REGULATORY_EXPANSION: Regulatory team hiring underway
  [+1.00] FUND_INCREASE_25: Viking Global increased 30%

Analysis: Smart money convergence with Perceptive (specialist biotech fund)
initiating a new position. Director purchase after joining board suggests
due diligence revealed opportunity. Regulatory hiring indicates potential
near-term submission.

--- ALNY (Alnylam Pharmaceuticals) ---
Composite Score: +5.10
Confidence: 68%
Recommendation: BUY

Score Breakdown:
  Insider Score:       +2.00
  Institutional Score: +2.50
  Hiring Score:        +1.50

Contributing Signals:
  [+2.50] MULTIPLE_FUNDS_INITIATE: 3 top funds initiated positions
  [+2.00] OFFICER_PURCHASE: VP R&D bought $80K
  [+1.50] MSL_HIRING: 4 Medical Science Liaison roles posted

Analysis: Three top biotech-focused funds initiating positions in same
quarter is a strong convergence signal. MSL hiring indicates pre-launch
preparation for commercial asset. R&D officer purchase suggests pipeline
confidence.

--- BEAM (Beam Therapeutics) ---
Composite Score: +1.20
Confidence: 45%
Recommendation: NEUTRAL

Score Breakdown:
  Insider Score:       +0.50
  Institutional Score: +0.50
  Hiring Score:        +0.50

Contributing Signals:
  [+0.80] OFFICER_PURCHASE: SVP bought $50K
  [+0.70] FUND_INCREASE_25: Tang Capital increased 30%

Analysis: Limited signal activity. Small officer purchase and modest fund
increase. Insufficient data for high-confidence directional call. Monitor
for additional signals.

--- EDIT (Editas Medicine) ---
Composite Score: -2.50
Confidence: 55%
Recommendation: NEUTRAL

Score Breakdown:
  Insider Score:       -1.50
  Institutional Score: -1.00
  Hiring Score:        +0.00

Contributing Signals:
  [-2.00] CFO_SALE: CFO sold $150K of shares (not 10b5-1)
  [-1.00] FUND_DECREASE_25: OrbiMed decreased 30%

Analysis: CFO selling outside of 10b5-1 plan is concerning - may indicate
financial concerns or lack of near-term catalyst confidence. Fund reduction
adds to negative sentiment. No positive hiring signals to offset.

--- BLUE (Bluebird Bio) ---
Composite Score: -5.20
Confidence: 70%
Recommendation: SELL

Score Breakdown:
  Insider Score:       -2.50
  Institutional Score: -1.50
  Hiring Score:        -2.00

Contributing Signals:
  [-3.00] MULTIPLE_INSIDER_SELL: 3 insiders sold in past 30 days
  [-2.00] FUND_EXIT: Boxer Capital exited position completely
  [-1.50] HIRING_FREEZE: 8 job postings removed in 2 weeks

Analysis: Strong bearish convergence. Multiple insiders selling in short
window suggests coordinated pessimism. Top fund complete exit is major
red flag. Job posting removals indicate potential cash runway concerns
or restructuring.

--- SAGE (Sage Therapeutics) ---
Composite Score: -6.80
Confidence: 75%
Recommendation: STRONG SELL

Score Breakdown:
  Insider Score:       -3.00
  Institutional Score: -2.50
  Hiring Score:        -2.50

Contributing Signals:
  [-3.00] CEO_SALE: CEO sold 15% of holdings (discretionary)
  [-3.00] MULTIPLE_FUNDS_EXIT: 3 top funds exited positions
  [-2.00] HIRING_FREEZE: 12 job postings removed
  [-1.50] CMO_DEPARTURE: Chief Medical Officer departed (Form 8-K)

Analysis: CRITICAL BEARISH SIGNALS. CEO large discretionary sale is rare
and highly informative. Multiple fund exits in same quarter indicates
loss of smart money confidence. Significant hiring freeze suggests
restructuring. CMO departure may indicate clinical/pipeline concerns.

================================================================================
TIME-DECAY CALCULATION EXAMPLE
================================================================================

Company: MRNA
Lookback Period: 90 days
Half-Life: 30 days

Signal                      Date         Raw Weight   Days Ago   Decay    Contrib
--------------------------  -----------  -----------  --------   ------   -------
CEO bought $200K            Jan 5        +5           10         0.75     +3.75
Baker Bros new position     Nov 26       +5           50         0.38     +1.90
8 commercial jobs posted    Dec 31       +5           15         0.67     +3.35
RA Capital increased 60%    Nov 26       +4           50         0.38     +1.52

Total Raw Score:                         +19
Total Weighted Score:                                            +10.52
Normalized Score (div 2):                                        +5.26
Clamped to [-10, +10]:                                          +5.26

Confidence Calculation:
  Sum of |weight| * decay = 3.75 + 1.90 + 3.35 + 1.52 = 10.52
  Confidence = min(1.0, 10.52 / 20) = 0.53

Final Score: +5.26
Confidence: 53%
Recommendation: BUY (score >= 3.0, confidence >= 0.5)

================================================================================
SIGNAL WEIGHTS REFERENCE
================================================================================

BULLISH SIGNALS (Positive Weights):
  +7: Activist investor files 13D (rare, high impact)
  +6: Multiple insiders buy in 30 days (coordinated optimism)
  +6: 3+ top funds initiate positions (smart money convergence)
  +5: CEO buys >$100K open market (extreme confidence)
  +5: CMO buys (clinical data confidence - very rare)
  +5: Top fund initiates new position
  +5: 5+ commercial roles posted (launch preparation)
  +5: MSL roles posted (pre-launch medical affairs)
  +4: CFO buys >$50K (financial health signal)
  +4: Top fund increases >50%
  +4: VP Manufacturing hired (scale-up signal)
  +4: Clinical operations expansion
  +3: Director buys after joining board
  +3: Regulatory team expansion (FDA submission prep)
  +2: Top fund increases >25%

BEARISH SIGNALS (Negative Weights):
  -7: Activist campaign against management
  -6: Multiple insiders sell in 30 days (coordinated pessimism)
  -6: 3+ top funds exit positions (smart money fleeing)
  -6: CMO departure (pipeline/data concerns)
  -5: CFO sells before quarter end (knows financials)
  -5: Top fund exits completely
  -5: C-suite sells after trial update (data not as good)
  -5: Clinical site hiring stops (enrollment problems)
  -4: CEO sells >10% of holdings
  -4: Top fund decreases >50%
  -4: Job postings removed en masse (hiring freeze)
  -4: Glassdoor mentions layoffs spike
  -3: Top fund decreases >25%

NEUTRAL/IGNORED:
  0: 10b5-1 plan transactions (pre-scheduled, not informative)
  0: Option exercises (typically tax-related)
  0: Transactions < $50K (noise threshold)

================================================================================
DATA SOURCES
================================================================================

1. SEC EDGAR - Form 4 (Insider Trading)
   - Real-time filings (within 2 business days of trade)
   - Distinguishes open market vs 10b5-1 plan trades
   - Updates: Continuous

2. SEC EDGAR - Form 13F (Institutional Holdings)
   - Quarterly filings (45 days after quarter end)
   - Position changes vs previous quarter
   - Updates: Quarterly

3. Company Career Pages (Job Postings)
   - Greenhouse, Lever, Workday platforms
   - Classification by department/seniority
   - Updates: Daily

4. SEC EDGAR - Form 8-K (Material Events) [Future]
   - Executive departures/hires
   - Material agreements
   - Updates: Real-time

================================================================================
DISCLAIMER
================================================================================

This report is for informational purposes only and does not constitute
investment advice. The signals and scores are based on publicly available
information and historical patterns. Past performance does not guarantee
future results.

Key Limitations:
- 13F data is 45+ days delayed
- Job postings may not reflect actual hiring decisions
- Insider trades may occur for personal reasons unrelated to company outlook
- Signal weights are based on historical correlations, not guarantees

Always conduct your own due diligence before making investment decisions.
The information may be incomplete or inaccurate.

================================================================================
REPORT END
================================================================================
